Stockscreener 앱 받기
4.95
3.56%
0.17
시간 외 거래:
4.92
-0.03
-0.61%
전일 마감가:
$4.78
열려 있는:
$4.81
하루 거래량:
2.48M
Relative Volume:
0.92
시가총액:
$621.28M
수익:
$50.27M
순이익/손실:
$-68.91M
주가수익비율:
-8.209
EPS:
-0.603
순현금흐름:
$-44.32M
1주 성능:
+2.91%
1개월 성능:
+6.22%
6개월 성능:
+24.37%
1년 성능:
-4.26%
1일 변동 폭
$4.775
$5.105
1주일 범위
$4.51
$5.105
52주 변동 폭
$2.93
$7.55
Aquestive Therapeutics Inc Stock (AQST) Company Profile
명칭
Aquestive Therapeutics Inc
전화
908-941-1900
주소
30 TECHNOLOGY DRIVE, WARREN, NJ
Compare AQST vs TAK, TEVA, HLN, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AQST
Aquestive Therapeutics Inc
|
4.95 | 599.95M | 50.27M | -68.91M | -44.32M | -0.603 |
TAK
Takeda Pharmaceutical Co Adr
|
18.95 | 58.31B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
39.52 | 43.22B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.25 | 40.41B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
72.86 | 30.15B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
497.59 | 21.32B | 3.17B | 1.29B | 1.01B | 27.09 |
Aquestive Therapeutics Inc Stock (AQST) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-24 | 재개 | Oppenheimer | Outperform |
| 2025-06-02 | 재개 | Oppenheimer | Outperform |
| 2024-12-17 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-05-10 | 개시 | Leerink Partners | Outperform |
| 2024-04-11 | 개시 | Piper Sandler | Overweight |
| 2024-03-28 | 개시 | Raymond James | Outperform |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2019-04-22 | 개시 | H.C. Wainwright | Buy |
| 2019-01-03 | 개시 | Lake Street | Buy |
| 2018-08-20 | 개시 | JMP Securities | Mkt Outperform |
| 2018-08-20 | 개시 | RBC Capital Mkts | Outperform |
모두보기
Aquestive Therapeutics Inc 주식(AQST)의 최신 뉴스
Aquestive (NASDAQ: AQST) CCO sells 8,750 shares after exercising options - Stock Titan
Cantor Fitzgerald reiterates Aquestive stock Overweight on Anaphylm profile By Investing.com - Investing.com Canada
Aquestive Therapeutics (AQST) insider adds 2,293 shares - Stock Titan
Aquestive at cantor healthcare conference: anaphylm launch nears By Investing.com - Investing.com Canada
Aquestive Therapeutics (AQST) CEO boosts stake with warrant exercise - Stock Titan
Aquestive Therapeutics (AQST) COO adds shares via warrant exercise - Stock Titan
Aquestive Therapeutics (AQST): Second Chance At Anaphylm Comes Into Focus - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeutics, Inc. (AQST) Investors to Inquire about Securities Investigation - ACCESS Newswire
AQST News | AQUESTIVE THERAPEUTICS INC (NASDAQ:AQST) - ChartMill
AQST SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aquestive Therapeutics, Inc. (AQST) And Encourages Stockholders to Reach Out - accessnewswire.com
Aquestive Therapeutics to Participate in Upcoming September Investor Conferences - Investing News Network
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aquestive Therapeutics, Inc. (AQST) And Encourages Stockholders to Connect - ACCESS Newswire
AQST INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Blue Owl Capital Holdings LP Makes New $3.92 Million Investment in Aquestive Therapeutics, Inc. $AQST - MarketBeat
Aquestive Therapeutics Earnings Call Highlights Anaphylm Progress - TipRanks
Latash Investments LLC Acquires New Holdings in Aquestive Therapeutics, Inc. $AQST - MarketBeat
Aquestive reports study results for Anaphylm allergy treatment By Investing.com - Investing.com Nigeria
Aquestive Therapeutics (NASDAQ:AQST) Sees Strong Trading VolumeTime to Buy? - MarketBeat
Aquestive Therapeutics: Potential Catalyst On The Horizon (NASDAQ:AQST) - Seeking Alpha
Aquestive (AQST) Q2 2026 Earnings Call Transcript - AOL.com
Aquestive Therapeutics CEO Daniel Barber Sells 25,000 Shares Under Rule 10b5-1 Plan - Kalkine Media
Aquestive (AQST) Closing Snapshot: Records a 0.70% Increase to $4.32 in the Current Update; Technical Focus - Vinanet
Aquestive Therapeutics CEO Daniel Barber disposes of 25,000 common shares worth $107,168 - Bitget
Aquestive (NASDAQ: AQST) CEO sells 25K shares under preset plan - Stock Titan
Aquestive Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Aquestive (NASDAQ: AQST) CCO's 2,714-share tax withholding detailed - Stock Titan
AQST INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeutics, Inc. (AQST) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeut - The National Law Review
2026-08-16 | Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeutics, Inc. (AQST) Stockholders to Inquire about Securities Investigation | NDAQ:AQST | Press Release - Stockhouse
Walleye Capital LLC Purchases New Stake in Aquestive Therapeutics, Inc. $AQST - MarketBeat
Aquestive Therapeutics (NASDAQ:AQST) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aquestive Therapeutics, Inc. (AQST) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
LifeSci Capital Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Wasatch Advisors LP Has $5.76 Million Position in Aquestive Therapeutics, Inc. $AQST - MarketBeat
Aquestive Therapeutics (AQST) Stock Faces Cash Burn Questions As Anaphylm Nears Resubmission - Sahm
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Aquestive Therapeutics Inc (AQST) (Q2 2026) Earnings Call Highlights: Anaphylm Resubmission on ... - Yahoo! Finance Canada
Earnings call transcript: Aquestive Therapeutics tops revenue views in Q2 2026 - Investing.com Nigeria
Aquestive Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Aquestive Therapeutics, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:AQST) 2026-08-12 - Seeking Alpha
Aquestive Therapeutics (NASDAQ:AQST) Shares Gap Down Following Weak Earnings - MarketBeat
Aquestive Therapeutics Q2 Earnings Call Highlights - MarketBeat
AQST: Q2 revenue up 38%, Anaphylm resubmission on track, and launch preparations advancing - TradingView
Aquestive Therapeutics, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Aquestive Therapeutics Q2 Loss Widens, Revenue Rises - Moomoo
Aquestive Plans to Take Epi Film Back to FDA with Positive Data - Allergic Living
Aquestive Therapeutics Latest Results: Sales guidance affirmed at $46-50M - scanx.trade
Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Aquestive Therapeutics Announces Q2 2026 Financial Results and Investor Presentation - Kalkine Media
Aquestive Therapeutics Inc (AQST) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.01%
1.37%
자본화:
|
볼륨(24시간):